Drug Profile
Tiragolumab - Genentech
Alternative Names: anti-TIGIT - Roche; MTIG-7192A; RG-6058; RG6058-10; RG6058-11; RO 7092284Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Genentech
- Developer Chugai Pharmaceutical; Genentech; National Cancer Institute (USA); Roche; Washington University School of Medicine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Liver cancer; Non-small cell lung cancer; Oesophageal cancer
- Phase II Cervical cancer; Gastric cancer; Malignant melanoma; Rectal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
- Phase I/II B-cell lymphoma
- No development reported Multiple myeloma; Triple negative breast cancer
Most Recent Events
- 25 Mar 2024 National Cancer Institute plans a phase II trial for Glioblastoma (Second-line or greater therapy, Adjuvant therapy) (IV) in June 2024 (NCT06328036)
- 20 Feb 2024 Washington University School of Medicine and Genentech terminate a phase II trial in Malignant melanoma (Combination therapy) in USA (IV) due to the Sponsor's decision (NCT05060003)
- 15 Feb 2024 Roche plans to file regulatory application for Oesophageal cancer (Late-stage disease) in or after 2026 (Roche pipeline, February 2024)